Dexmedetomidine hydrochloride as a long-term sedative

Area of Science:

• Anesthesiology
• Critical Care Medicine
• Pharmacology

Background:

• Dexmedetomidine is a sedative with minimal respiratory impact, approved in the US in 1999.
• Prolonged use (over 24 hours) was approved in Colombia and the Dominican Republic in 2008, with increasing global approvals.
• Concerns exist regarding long-term sedative efficacy and safety in intensive care settings.

Purpose of the Study:

• To review existing literature on the prolonged use of dexmedetomidine.
• To confirm the efficacy and safety of dexmedetomidine infusions exceeding 24 hours.
• To evaluate dexmedetomidine as an alternative to traditional sedatives.

Main Methods:

• Literature review of studies on prolonged dexmedetomidine use.
• Analysis of data from adult patients receiving dexmedetomidine at doses of 0.1-2.5 μg/kg/hour for up to 30 days.
• Comparison of adverse effects and efficacy with benzodiazepines and propofol.

Main Results:

• Dexmedetomidine infusions up to 30 days are effective and safe.
• Lower incidences of delirium and coma compared to benzodiazepines and propofol.
• Mild adverse effects like bradycardia were noted; no serious adverse effects reported.
• Efficacy in pediatric patients for extubation and as an alternative sedative is suggested, but controlled studies are lacking.

Conclusions:

• Prolonged dexmedetomidine infusion is a safe and effective alternative for adult sedation.
• It offers advantages over benzodiazepines and propofol regarding delirium and coma.
• Further research is needed to establish definitive efficacy and safety in pediatric populations.